Walldorf, 17.01.2014 - B. Braun Melsungen AG was founded 175 years ago in a pharmacy in the center of Melsungen. The headquarters of the pharmaceutical and medical supply company remain here today, although the company continues to grow substantially beyond its roots. Today, B. Braun has a presence in 60 countries and 46,500 employees worldwide, with approximately 12,000 in Germany (2012). The company generated sales around five billion euro in 2012.
High-Tech Gründerfonds (HTGF) invests venture capital in young technology companies with potential that convert promising research results into business opportunities. Investors in the public-private partnership include the German Federal Ministry of Research and Technology, the KfW Group, as well as 18 commercial enterprises, including B. Braun. They analyze the innovation projects (proposals) offered by the HTGF, looking for software to build and support valuation and decision processes.
B. Braun is using target Idea Management software to manage the HTGF proposals. The company had already been using target software since 2009 for idea management. In 2013, a completely new configuration based on this software was set up for HTGF innovation management.
The software maps the process as follows: an author submits the HTGF proposal in the database and then an assessor registers the proposal by assigning it to one or more of eight corporate divisions. During the assignment process, innovators are integrated into the workflow. In addition to text-based opinions, supporting documents can be attached, as well as voting/assessment options based on various criteria (including market evaluation, technical evaluation, compatibility with the portfolio). Expert opinions can also be requested. The system provides a convenient overview of all opinions und evaluations. Based on this data, the assessor creates the draft for a decision on investment.
"target software helps us support our decision process online and without much effort. The SAP software-based platform allows us to integrate all necessary experts and guarantees the required security and robustness." - Dr. Alexander Schachtrupp, Chief Medical Officer, B. Braun Corporate
Für den Inhalt der Pressemitteilung ist der Einsteller, PresseBox.de, verantwortlich.
Es wurde noch kein Kommentar zu diesem Thema abgegeben.